Empowered Patient Podcast

Dr. Hernan Bazan is the CEO and Co-Founder of South Rampart Pharma and focuses on finding a new way to treat acute and chronic pain with a drug that has no expectation for abuse and is not toxic to the liver, kidneys, or cardiovascular system.

Hernan explains, "This is a tremendous unmet need in that there really has been no innovation in the pain space for over 50 years. Tylenol itself, acetaminophen, Tylenol was born in the '40s and the early '50s and worked by actually someone that was at the NIH that came to visit us a few times, a very well renowned neuroscientist. And he really discovered it incidentally, looking for another pathway, but we won't go into that. And that was adopted by McNeil Laboratories, and then eventually Johnson & Johnson."

"And then, in the '60s and '70s, non-steroidals, non NSAIDs, were marketed as Advil and ibuprofen, and a bunch of NSAIDs were derived. And these are very good medicines for preventing inflammation and treating pain in the short term. The challenge with both of these classes of pain meds is that they have risks."

"And then the third class, obviously, everybody knows about opioids and how they were marketed in the '90s."

@SR_Pharma #Pain #AcutePain #Analgesic #Acetaminophen #Opioid #NSAID #Nontoxic #NonOpioid #NewOrleans

southrampartpharma.com

Listen to the podcast here

Dr. Hernan Bazan is the CEO and Co-Founder of South Rampart Pharma and focuses on finding a new way to treat acute and chronic pain with a drug that has no expectation for abuse and is not toxic to the liver, kidneys, or cardiovascular system.

Hernan explains, "This is a tremendous unmet need in that there really has been no innovation in the pain space for over 50 years. Tylenol itself, acetaminophen, Tylenol was born in the '40s and the early '50s and worked by actually someone that was at the NIH that came to visit us a few times, a very well renowned neuroscientist. And he really discovered it incidentally, looking for another pathway, but we won't go into that. And that was adopted by McNeil Laboratories, and then eventually Johnson & Johnson."

"And then, in the '60s and '70s, non-steroidals, non NSAIDs, were marketed as Advil and ibuprofen, and a bunch of NSAIDs were derived. And these are very good medicines for preventing inflammation and treating pain in the short term. The challenge with both of these classes of pain meds is that they have risks."

"And then the third class, obviously, everybody knows about opioids and how they were marketed in the '90s."

@SR_Pharma #Pain #AcutePain #Analgesic #Acetaminophen #Opioid #NSAID #Nontoxic #NonOpioid #NewOrleans

southrampartpharma.com

Download the transcript here

Sheila Frame is the President for the Americas at Amryt Pharma, founded on the belief that rare and ultra-rare diseases were an opportunity to support underserved patients differently than the big pharmaceutical companies could. With the acquisition of Mycapssa, Amryt is changing the treatment for the rare disease acromegaly from painful injections to the first and only twice-daily oral medication.

Shelia explains, "We're currently commercially, at least, in three different areas. So lipodystrophy is a pretty significant leptin deficiency for people who suffer from that. It's a fairly rare disease, with about 300 patients roughly in the US. The second one is in homozygous familial hypercholesterolemia, and again, a very rare genetic disease, probably even fewer patients than what we see in lipodystrophy. And then the third area, of course, is acromegaly with Mycapssa, where we actually have products in the market."

"I think what's interesting about not only the technology that we have with Mycapssa but also the impact of taking a pill twice a day means that you have this sustained control of the drug in your system. I think patients are finding that that really helps them. And so beyond just the convenience of not having to go through monthly objections, but also just the way they feel by having that sustained control and the drug in their system."

@AmrytPharma #Amryt #Acromegaly #Endocrinology #RareDisease #Mycapssa

Acromegalycommunity.org

Amrytpharma.com

Download the transcript here

Sheila Frame is the President for the Americas at Amryt Pharma, founded on the belief that rare and ultra-rare diseases were an opportunity to support underserved patients differently than the big pharmaceutical companies could. With the acquisition of Mycapssa, Amryt is changing the treatment for the rare disease acromegaly from painful injections to the first and only twice-daily oral medication.

Shelia explains, "We're currently commercially, at least, in three different areas. So lipodystrophy is a pretty significant leptin deficiency for people who suffer from that. It's a fairly rare disease, with about 300 patients roughly in the US. The second one is in homozygous familial hypercholesterolemia, and again, a very rare genetic disease, probably even fewer patients than what we see in lipodystrophy. And then the third area, of course, is acromegaly with Mycapssa, where we actually have products in the market."

"I think what's interesting about not only the technology that we have with Mycapssa but also the impact of taking a pill twice a day means that you have this sustained control of the drug in your system. I think patients are finding that that really helps them. And so beyond just the convenience of not having to go through monthly objections, but also just the way they feel by having that sustained control and the drug in their system."

@AmrytPharma #Amryt #Acromegaly #Endocrinology #RareDisease #Mycapssa

Acromegalycommunity.org

Amrytpharma.com

Download the transcript here

Allison London Brown is the CEO of LUMINELLE, inventors of an advanced endoscopic system with a camera and biopsy device that allows physicians to perform gynecological procedures in their offices more safely, more efficiently, and with better reimbursement. Being able to look inside the uterus and bladder and perform operations that in the past would have required a hospital outpatient visit means that women and their doctors are more likely to identify problems sooner and get a prompt diagnosis of cancerous tissues.

Allison elaborates, "If you have problems, it can also help with things like drug delivery for overactive bladder. And it can be used for fertility, both treatments, as well as trying to prevent pregnancy. So it's a pretty versatile system. It's very low cost, and it's really so that women can have procedures done in the comfort of their physician's office with less anesthesia and certainly less cost."

"And for the payers, if you're catching things sooner, you're not incurring all these costs that you might in a hospital, like the anesthesiologist and all the nurses and all the different things that go along with the hospital outpatient procedure. It's much more beneficial for them as well. So it's really a nice move to try to get people care the first time at the first place they should be going."

#LUMINELLE #Endoscopy #MedicalDevice #WomensHealth #UterineCancer

LUMINELLE360.com

Listen to the podcast here

Allison London Brown is the CEO of LUMINELLE, inventors of an advanced endoscopic system with a camera and biopsy device that allows physicians to perform gynecological procedures in their offices more safely, more efficiently, and with better reimbursement. Being able to look inside the uterus and bladder and perform operations that in the past would have required a hospital outpatient visit means that women and their doctors are more likely to identify problems sooner and get a prompt diagnosis of cancerous tissues.

Allison elaborates, "If you have problems, it can also help with things like drug delivery for overactive bladder. And it can be used for fertility, both treatments, as well as trying to prevent pregnancy. So it's a pretty versatile system. It's very low cost, and it's really so that women can have procedures done in the comfort of their physician's office with less anesthesia and certainly less cost."

"And for the payers, if you're catching things sooner, you're not incurring all these costs that you might in a hospital, like the anesthesiologist and all the nurses and all the different things that go along with the hospital outpatient procedure. It's much more beneficial for them as well. So it's really a nice move to try to get people care the first time at the first place they should be going."

#LUMINELLE #Endoscopy #MedicalDevice #WomensHealth #UterineCancer

LUMINELLE360.com

Download the transcript here

Dr. Emily Hamilton is the Senior Vice President of Clinical Research at PeriGen, which is applying artificial intelligence and machine learning to early warning and clinical decision support in healthcare. With a focus on labor and delivery, PeriGen is providing real-time information to clinicians to drive down the likelihood of birth-related brain injury.

Emily explains, "So, what we have developed is an AI machine learning-based way of looking at the tracing to identify contractions, to notify nurses and doctors that there are excessive contractions, and that's gone on for a while. We've also used that to recognize patterns in the fetal heart rate, which indicate that the baby's not responding well to labor and to notify them of that so that they can intervene and prevent the adverse outcome."

"Likewise, we can look at the labor, and we can compare a patient's labor to a group of similar women who are having the same frequency of contractions, a number of other variables, and indicate whether or not this labor is on course or whether or not it's slower or perhaps faster. It's all done in a very consistent, quantifiable way."

@PeriGen #AI #ArtificialIntelligence #MachineLearning #ML #WomensHealth #LaborandDelivery #BirthRelatedBrainInjury

Perigen.com

Listen to the podcast here

Dr. Emily Hamilton is the Senior Vice President of Clinical Research at PeriGen, which is applying artificial intelligence and machine learning to early warning and clinical decision support in healthcare. With a focus on labor and delivery, PeriGen is providing real-time information to clinicians to drive down the likelihood of birth-related brain injury.

Emily explains, "So, what we have developed is an AI machine learning-based way of looking at the tracing to identify contractions, to notify nurses and doctors that there are excessive contractions, and that's gone on for a while. We've also used that to recognize patterns in the fetal heart rate, which indicate that the baby's not responding well to labor and to notify them of that so that they can intervene and prevent the adverse outcome."

"Likewise, we can look at the labor, and we can compare a patient's labor to a group of similar women who are having the same frequency of contractions, a number of other variables, and indicate whether or not this labor is on course or whether or not it's slower or perhaps faster. It's all done in a very consistent, quantifiable way."

@PeriGen #AI #ArtificialIntelligence #MachineLearning #ML #WomensHealth #LaborandDelivery #BirthRelatedBrainInjury

Perigen.com

Download the transcript here

Arjan Haverhals is the CEO and President of Milestone Scientific, which is exploring how to modernize hypodermic syringe use. One application of their injection technology is for women during labor and delivery to inject the epidural needle more accurately and control the pain. Milestone is also looking at dentistry, chronic pain, neuro-surgery, and cosmetic medicine as additional opportunities to deliver more efficient, precise, and safer injections.

Arjan provides a historical perspective, "Just to give you some background information from a study from last year. It was found that even when male and female patients expressed the same amount of pain, female patients' pain is often seen as less intense and more likely to benefit from psychotherapy versus medication as compared to men's pain. And I do believe that this gender gap in healthcare could lead to bias diagnoses related to chronic pain for women and may also explain why very little has changed in the field of epidural delivery. And any way we can aid in closing that gap is a win-win."

"Now, if women go for labor and delivery these days, it is still a technology that is used stemming from the 1860s, and it is nothing more or less than a hypodermic syringe, later positioned in the medical field as the loss of resistance technique, which is a very manual, subjective way of placing the epidural needle in the epidural space. And the reason why we entered this field is a strong belief that we can solve the problems, and the associated risk factors, with this high-risk epidural analgesia procedure."

@MilestoneSciInc #CompuFlov#WomensHealth #Pregnancy #LaborandDelivery #Epidural #DuralPuncture #MedicalDevice #MedTech

MilestoneScientific.com

Listen to the podcast here

Arjan Haverhals is the CEO and President of Milestone Scientific, which is exploring how to modernize hypodermic syringe use. One application of their injection technology is for women during labor and delivery to inject the epidural needle more accurately and control the pain. Milestone is also looking at dentistry, chronic pain, neuro-surgery, and cosmetic medicine as additional opportunities to deliver more efficient, precise, and safer injections.

Arjan provides a historical perspective, "Just to give you some background information from a study from last year. It was found that even when male and female patients expressed the same amount of pain, female patients' pain is often seen as less intense and more likely to benefit from psychotherapy versus medication as compared to men's pain. And I do believe that this gender gap in healthcare could lead to bias diagnoses related to chronic pain for women and may also explain why very little has changed in the field of epidural delivery. And any way we can aid in closing that gap is a win-win."

"Now, if women go for labor and delivery these days, it is still a technology that is used stemming from the 1860s, and it is nothing more or less than a hypodermic syringe, later positioned in the medical field as the loss of resistance technique, which is a very manual, subjective way of placing the epidural needle in the epidural space. And the reason why we entered this field is a strong belief that we can solve the problems, and the associated risk factors, with this high-risk epidural analgesia procedure."

@MilestoneSciInc #CompuFlov#WomensHealth #Pregnancy #LaborandDelivery #Epidural #DuralPuncture #MedicalDevice #MedTech

MilestoneScientific.com

Download the transcript here